Zobrazeno 1 - 10
of 92
pro vyhledávání: '"L, Kayitalire"'
Autor:
G.A. De Velasco Oria, E. Garralda, V. Moreno Garcia, I. Melero, I. Victoria Ruiz, A. Indacochea, A. Cervantes, A. Oberoi, D. Jones, M.A. Lakins, L. Kayitalire
Publikováno v:
Immuno-Oncology and Technology. 16:100285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e93128953ac1c315778f6baee733927b
https://doi.org/10.1016/j.iotech.2022.100285
https://doi.org/10.1016/j.iotech.2022.100285
Autor:
Timothy A. Yap, Kyriakos P. Papadopoulos, L. Kayitalire, Sarina Anne Piha-Paul, C.J. Shepherd, U.B. Grabowska, Siwen Hu-Lieskovan, J-B. Holz, Patricia LoRusso, S. Marshall, E. Poon
Publikováno v:
Annals of Oncology. 32:S864-S865
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::694186a48b249e62092a44c6abae546c
https://doi.org/10.1016/j.annonc.2021.08.1417
https://doi.org/10.1016/j.annonc.2021.08.1417
Autor:
E. Garralda, I. Melero, G. de Velasco, V. Moreno, H.K. Oberoi, C. Shepherd, D. Jones, M.A. Lakins, P. Hurley, S. Khambhatwala, D. Long, L. Kayitalire
Publikováno v:
Annals of Oncology. 32:S1454
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::093bc20933c7f362b5a8b1507e42365a
https://doi.org/10.1016/j.annonc.2021.10.184
https://doi.org/10.1016/j.annonc.2021.10.184
Autor:
Stefan Paepke, Antonio Llombart-Cussac, Maik Hauschild, F Kasiborski, J.-P. Machiels, M Venturini, Mahdi Rezai, L Kayitalire, S Pernas-Simon, E Luporsi
Publikováno v:
Cancer Research. 71:P3-14
Background The upfront addition of trastuzumab (Herceptin, H) to anthracycline/taxane-based primary chemotherapy significantly increases pathological complete response (pCR) in HER2−positive breast cancer (BC) patients (pts). However, concerns abou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::219e3cb49a60473064a42f487454aff4
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-13
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-13
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Véronique Diéras, L. Kayitalire, Pierre Fumoleau, Marc Espié, Patrice Viens, Eric Pujade-Lauraine, Pierre Pouillart, Mario Campone, Laurence Bozec, Thierry Petit, Daniel Serin
Publikováno v:
The Breast. 15:601-609
Gemcitabine and epirubicin were evaluated in metastatic breast cancer (MBC) patients to determine the maximum tolerated dose (MTD), efficacy, and toxicity of the combination. Patients initially received 800 mg/m(2) of gemcitabine (days 1 and 8) and 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec16178965ccc15c37c497e78055bcd7
https://doi.org/10.1016/j.breast.2005.11.010
https://doi.org/10.1016/j.breast.2005.11.010
Publikováno v:
British Journal of Cancer
The relevance of gemcitabine timing for chronotherapeutic optimisation was investigated. Healthy mice received multiple doses of gemcitabine (120, 160 or 200 mg kg(-1) injection (inj)(-1)) at one of six circadian times (3, 7, 11, 15, 19 or 23 h after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8e824a85906914927a869f51f38d072
https://doi.org/10.1038/sj.bjc.6602564
https://doi.org/10.1038/sj.bjc.6602564
Autor:
Moïse Namer, Christoph C. Zielinski, A. duBois, Laurent Zelek, M. Spielmann, A. Casado, D. Dodwell, L. Kayitalire, Eva Carrasco, Michael J. Lind, A. Lluch, P. Vodvarka, Hilary Calvert, C. Unger, M. Martin
Publikováno v:
Annals of Oncology. 14:1246-1252
Background To assess antitumor activity and toxicity of pemetrexed in metastatic breast cancer (MBC) patients previously treated with anthracyclines. Patients and methods Seventy-seven MBC patients from 12 European institutions were entered into the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8a456d23b62c346c9cbe3158eff3e68
https://doi.org/10.1093/annonc/mdg339
https://doi.org/10.1093/annonc/mdg339
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
François Lokiec, L. Kayitalire, Silvia Novello, Sandrine Faivre, T. Le Chevalier, Julien Taieb, Eric Raymond, Catherine Lhommé, C. Monnerat, Pierre Ruffié, Patricia Pautier, J.P. Armand
Publikováno v:
Annals of Oncology. 13:1479-1489
Background The aim of this study was to determine the toxicity profile, the recommended dose (RD) and the pharmacokinetic parameters, and to evaluate the antitumor activity of gemcitabine combined with oxaliplatin in patients with advanced non-small-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74d0c764a186dbdb88b0035b119acd2
https://doi.org/10.1093/annonc/mdf219
https://doi.org/10.1093/annonc/mdf219